Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: Is there something here?

Quality of Life Research

Volumn 22, Issue 1, 2013, Pages 75-84

  Aucott, John N ^a   Rebman, Alison W ^b   Crowder, Lauren A ^b   Kortte, Kathleen B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Lyme Disease Research Foundation of Maryland   (United States)

Author keywords

Chronic disease; Depression; Life functioning; Outcomes; Post treatment Lyme disease syndrome

Indexed keywords

ADULT; COMPLICATION; DAILY LIFE ACTIVITY; DEPRESSION; FATIGUE; FEMALE; GEOGRAPHIC TONGUE; HUMAN; LYME DISEASE; MALE; MENTAL HEALTH; MIDDLE AGED; PAIN; PERSONALITY TEST; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; SOCIAL ADAPTATION; SYNDROME; ARTICLE; ERYTHEMA CHRONICUM MIGRANS;

ACTIVITIES OF DAILY LIVING; ADULT; DEPRESSION; FATIGUE; FEMALE; GLOSSITIS, BENIGN MIGRATORY; HUMANS; LYME DISEASE; MALE; MENTAL HEALTH; MIDDLE AGED; PAIN; PERSONALITY INVENTORY; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; SOCIAL ADJUSTMENT; SYNDROME;

EID: 84872678519     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-012-0126-6     Document Type: Article

References (41)

1. Reported Lyme disease cases by state, 1996-2009. http://www.cdc.gov/lyme/ stats/charstables/reportedcases-statelocality.html.
2. Meek, J. I.; Roberts, C. L.; Smith, E. V.; Jr.; & Cartter, M. L. (1996). Underreporting of Lyme disease by Connecticut physicians, 1992. Journal of Public Health Management and Practice, 2(4), 61-65.
3. Nadelman, R. B.; Nowakowski, J.; Forseter, G.; Goldberg, N. S.; Bittker, S.; Cooper, D.; et al. (1996). The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. American Journal of Medicine, 100(5), 502-508.
4. Steere, A. C.; Dhar, A.; Hernandez, J.; Fischer, P. A.; Sikand, V. K.; Schoen, R. T.; et al. (2003). Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease. American Journal of Medicine, 114(1), 58-62.
5. Liveris, D.; Schwartz, I.; Bittker, S.; Cooper, D.; Iyer, R.; Cox, M. E.; et al. (2011). Improving the yield of blood cultures from patients with early Lyme disease. Journal of Clinical Microbiology, 49(6), 2166-2168.
6. Steere, A. C. (2001). Lyme disease. New England Journal of Medicine, 345(2), 115-125.
7. Logigian, E. L.; Kaplan, R. F.; & Steere, A. C. (1990). Chronic neurologic manifestations of Lyme disease. New England Journal of Medicine, 323(21), 1438-1444.
8. Steere, A. C.; Schoen, R. T.; & Taylor, E. (1987). The clinical evolution of Lyme arthritis. Annals of Internal Medicine, 107(5), 725-731.
9. Wormser, G. P. (2006). Clinical practice. Early Lyme disease. New England Journal of Medicine, 354(26), 2794-2801.
10. Steere, A. C.; Hutchinson, G. J.; Rahn, D. W.; Sigal, L. H.; Craft, J. E.; DeSanna, E. T.; et al. (1983). Treatment of the early manifestations of Lyme disease. Annals of Internal Medicine, 99(1), 22-26.
11. Luft, B. J.; Dattwyler, R. J.; Johnson, R. C.; Luger, S. W.; Bosler, E. M.; Rahn, D. W.; et al. (1996). Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Annals of Internal Medicine, 124(9), 785-791.
12. Wormser, G. P.; Ramanathan, R.; Nowakowski, J.; McKenna, D.; Holmgren, D.; Visintainer, P.; et al. (2003). Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 138(9), 697-704.
13. Asch, E. S.; Bujak, D. I.; Weiss, M.; Peterson, M. G.; & Weinstein, A. (1994). Lyme disease: an infectious and postinfectious syndrome. Journal of Rheumatology, 21(3), 454-461.
14. Dinerman, H.; & Steere, A. C. (1992). Lyme disease associated with fibromyalgia. Annals of Internal Medicine, 117(4), 281-285.
15. Wormser, G. P.; Dattwyler, R. J.; Shapiro, E. D.; Halperin, J. J.; Steere, A. C.; Klempner, M. S.; et al. (2006). The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases, 43(9), 1089-1134.
16. Kalish, R. A.; Kaplan, R. F.; Taylor, E.; Jones-Woodward, L.; Workman, K.; & Steere, A. C. (2001). Evaluation of study patients with Lyme disease, 10-20-year follow-up. Journal of Infectious Diseases, 183(3), 453-460.
17. Nowakowski, J.; Nadelman, R. B.; Sell, R.; McKenna, D.; Cavaliere, L. F.; Holmgren, D.; et al. (2003). Long-term follow-up of patients with culture-confirmed Lyme disease. American Journal of Medicine, 115(2), 91-96.
18. Shadick, N. A.; Phillips, C. B.; Sangha, O.; Logigian, E. L.; Kaplan, R. F.; Wright, E. A.; et al. (1999). Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Annals of Internal Medicine, 131(12), 919-926.
19. Klempner, M. S.; Hu, L. T.; Evans, J.; Schmid, C. H.; Johnson, G. M.; Trevino, R. P.; et al. (2001). Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. New England Journal of Medicine, 345(2), 85-92.
20. Sigal, L. H.; & Hassett, A. L. (2005). Commentary: 'what's in a name? That which we call a rose by any other name would smell as sweet'. Shakespeare W. Romeo and Juliet, II, ii (47-48). International Journal of Epidemiology, 34(6), 1345-1347.
21. Beck, A. T.; Steer, R. A.; & Brown, G. K. (1996). Manual for the Beck Depression Inventory (BDI-II) (2nd ed.). San Antonio, TX: The Psychological Association.
22. Osman, A.; Downs, W. R.; Barrios, F. X.; Kopper, B. A.; Gutierrez, P. M.; & Chiros, C. E. (1997). Factor structure and psychometric characteristics of the Beck Depression Inventory-II. Journal of Psychopathology and Behavior Assessment, 19, 359.
23. Steer, R.; Ball, R.; Ranieri, W.; & Beck, A. (1999). Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. Journal of Clinical Psychology, 55(1), 117.
24. Ware, J. E.; Kosinski, M.; & Dewey, J. E. (2000). How to score version 2 of the SF-36 health survey. Lincoln, RI: QualityMetric Incorporated.
25. Diggle, P. J.; Heagerty, P.; Liang, K. Y.; & Zeger, S. L. (2002). Analysis of longitudinal data (2nd ed.). Oxford: Oxford University Press.
26. Jason, L. A.; Taylor, R. R.; & Kennedy, C. L. (2000). Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms. Psychosomatic Medicine, 62(5), 655-663.
27. Cerar, D.; Cerar, T.; Ruzic-Sabljic, E.; Wormser, G. P.; & Strle, F. (2010). Subjective symptoms after treatment of early Lyme disease. The American Journal of Medicine, 123(1), 79.
28. Hickie, I.; Davenport, T.; Wakefield, D.; Vollmer-Conna, U.; Cameron, B.; Vernon, S. D.; et al. (2006). Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ, 333(7568), 575.
29. Meeus, M.; & Nijs, J. (2007). Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clinical Rheumatology, 26(4), 465-473.
30. Chandra, A.; Wormser, G. P.; Marques, A. R.; Latov, N.; & Alaedini, A. (2011). Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome. Clinical and Vaccine Immunology, 18(5), 767-771.
31. Steere, A. C.; & Glickstein, L. (2004). Elucidation of Lyme arthritis. Nature Reviews Immunology, 4(2), 143-152.
32. Barthold, S. W.; Hodzic, E.; Imai, D. M.; Feng, S.; Yang, X.; & Luft, B. J. (2010). Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrobial Agents and Chemotherapy, 54(2), 643-651.
33. Seltzer, E. G.; Gerber, M. A.; Cartter, M. L.; Freudigman, K.; & Shapiro, E. D. (2000). Long-term outcomes of persons with Lyme disease. JAMA, 283(5), 609-616.
34. Cairns, V.; & Godwin, J. (2005). Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. International Journal of Epidemiology, 34, 1340.
35. Kroenke, K.; & Mangelsdorff, A. D. (1989). Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. American Journal of Medicine, 86(3), 262-266.
36. Weir, P. T.; Harlan, G. A.; Nkoy, F. L.; Jones, S. S.; Hegmann, K. T.; Gren, L. H.; et al. (2006). The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes. Journal of Clinical Rheumatology, 12(3), 124-128.
37. Roelofs, K.; & Spinhoven, P. (2007). Trauma and medically unexplained symptoms towards an integration of cognitive and neuro-biological accounts. Clinical Psychology Review, 27(7), 798-820.
38. Bujak, D. I.; Weinstein, A.; & Dornbush, R. L. (1996). Clinical and neurocognitive features of the post Lyme syndrome. Journal of Rheumatology, 23(8), 1392-1397.
39. Hassett, A.; Radvanski, D.; Buyske, S.; Savage, S.; Gara, M.; Escobar, J.; et al. (2008). Role of psychiatric comorbidity in chronic Lyme disease. Arthritis and Rheumatism, 59(12), 1742.
40. Kaplan, R. F.; Meadows, M. E.; Vincent, L. C.; Logigian, E. L.; & Steere, A. C. (1992). Memory impairment and depression in patients with Lyme encephalopathy: comparison with fibromyalgia and nonpsychotically depressed patients. Neurology, 42(7), 1263-1267.
41. Elkins, L. E.; Pollina, D. A.; Scheffer, S. R.; & Krupp, L. B. (1999). Psychological states and neuropsychological performances in chronic Lyme disease. Applied Neuropsychology, 6(1), 19-26.